A single amino acid in the F2 subunit of respiratory syncytial virus fusion protein alters growth and fusogenicity

Respiratory syncytial virus (RSV) causes severe lower respiratory tract infection in children, especially in infants less than 1 year of age. There are currently no licensed vaccines against RSV. rA2ΔM2-2 is a promising live-attenuated vaccine candidate that is currently being evaluated in the clini...

Full description

Saved in:
Bibliographic Details
Published inJournal of general virology Vol. 94; no. 12; pp. 2627 - 2635
Main Authors Lawlor, Heather A., Schickli, Jeanne H., Tang, Roderick S.
Format Journal Article
LanguageEnglish
Published England Society for General Microbiology 01.12.2013
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Respiratory syncytial virus (RSV) causes severe lower respiratory tract infection in children, especially in infants less than 1 year of age. There are currently no licensed vaccines against RSV. rA2ΔM2-2 is a promising live-attenuated vaccine candidate that is currently being evaluated in the clinic. Attenuation of rA2ΔM2-2 is achieved by a single deletion of the M2-2 gene, which disrupts the balance between viral transcription and replication. Whilst performing a manufacturing feasibility study in a serum-free adapted Vero cell line, differences in growth kinetics and cytopathic effect (CPE) were identified between two rA2ΔM2-2 vaccine candidates. Comparative sequence analysis identified four amino acid differences between the two vaccine viruses. Recombinant rA2ΔM2-2 viruses carrying each of the four amino acid differences identified a K66E mutation in the F 2 fragment of the fusion (F) protein as the cause of the growth and CPE differences. Syncytium-formation experiments with RSV F protein carrying mutations at aa 66 suggested that a change in charge at this residue within the F 2 fragment can have a significant impact on fusion.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-1317
1465-2099
1465-2099
DOI:10.1099/vir.0.055368-0